The cost-effectiveness of risk-stratified breast cancer screening in the UK
- PMID: 37848734
- PMCID: PMC10667489
- DOI: 10.1038/s41416-023-02461-1
The cost-effectiveness of risk-stratified breast cancer screening in the UK
Abstract
Background: There has been growing interest in the UK and internationally of risk-stratified breast screening whereby individualised risk assessment may inform screening frequency, starting age, screening instrument used, or even decisions not to screen. This study evaluates the cost-effectiveness of eight proposals for risk-stratified screening regimens compared to both the current UK screening programme and no national screening.
Methods: A person-level microsimulation model was developed to estimate health-related quality of life, cancer survival and NHS costs over the lifetime of the female population eligible for screening in the UK.
Results: Compared with both the current screening programme and no screening, risk-stratified regimens generated additional costs and QALYs, and had a larger net health benefit. The likelihood of the current screening programme being the optimal scenario was less than 1%. No screening amongst the lowest risk group, and triannual, biennial and annual screening amongst the three higher risk groups was the optimal screening strategy from those evaluated.
Conclusions: We found that risk-stratified breast cancer screening has the potential to be beneficial for women at the population level, but the net health benefit will depend on the particular risk-based strategy.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
References
-
- Public Health England. Breast screening for women with a high risk of breast cancer. https://www.gov.uk/government/publications/nhs-breast-screening-high-ris.... Accessed 25 February 2023.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical